Therapy Market Research Reports & Industry Analysis

Defined as treatment of disabilities/illnesses (physical and mental), therapy represents an essential branch of medicine. This term is widely used by psychologists to describe the session between them and patients. Depending on an illness, different therapies types are applied. Therapies may be aimed at the prevention of the disease occurrence, stopping its further progress or preventing an outbreak. They may be also used to improve a patient’s comfort.

Therapies are classified on the basis of energy (e.g. phototherapy and thermotherapy), human interaction (for instance, psychotherapy and psychotherapy) and matter (e.g. gene therapy and biotherapy), etc.

The Catalogue is an unprecedented source of research reports analyzing the therapy market in detail. The reports uncover the market sizing and segmentation, its present standing and future prospects. The research studies investigate the competitive environment and contain majors’ profiles. Market igniters and limiters are scrutinized, and trends and future opportunities are unveiled in the reports.

Found 2086 publications
Type 2 Diabetes Mellitus - Heat Map and Analysis US$ 2,000.00

Type 2 Diabetes Mellitus - Heat Map and Analysis Summary Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia ( ...

Sep, 2016 19 pages
Type 1 Diabetes Mellitus - Heat Map and Analysis US$ 2,000.00

Type 1 Diabetes Mellitus - Heat Map and Analysis Summary Type I diabetes mellitus (T1DM) is a metabolic disease characterized by chronic hyperglycemia, and is caused by defective ... day. Furthermore, the disease is associated with organ failure and diabetic ketoacidosis, which are both potentially fatal side-effects. The ...

Oct, 2016 17 pages
Cystic Fibrosis - Heat Map and Analysis US$ 2,000.00

Cystic Fibrosis - Heat Map and Analysis Summary Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene ...

Nov, 2016 13 pages
Chronic Obstructive Pulmonary Disease - Heat Map and Analysis US$ 2,000.00

Chronic Obstructive Pulmonary Disease - Heat Map and Analysis Summary Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties ... limitation. Both parenchymal destruction – termed emphysema – and small airways disease – referred to as chronic bronchitis – contribute towards these changes, which occur in varying ...

Jun, 2016 15 pages
Alzheimer's Disease - Heat Map and Analysis US$ 2,000.00

Alzheimer's Disease - Heat Map and Analysis Summary Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. The ... function, managing behavioural symptoms and slowing down the rate of disease progression. There is currently no cure for AD, and only six symptomatic ...

Nov, 2016 16 pages
Acute Myeloid Leukemia - Heat Map and Analysis US$ 2,000.00

Acute Myeloid Leukemia - Heat Map and Analysis Summary Acute Myeloid Leukemia (AML) is a rare but serious disease, and the most common leukemia suffered by adults. The first-line ... AML has the lowest five-year survival rate of all leukemias, at 25%. Efforts have been made to introduce novel therapies to the AML ...

Mar, 2016 10 pages
Global Infantile Spasms Therapeutics Market 2017-2021 US$ 3,500.00

... the sales of infantile spasms therapuetics. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape ...

Dec, 2016 73 pages
Usher Syndrome - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Usher Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development ...

Dec, 2016 38 pages
Hyperinsulinemia - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Hyperinsulinemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development ...

Dec, 2016 41 pages
Global Radiotherapy Market by Products (Proton Therapy, Linear Accelerator, CyberKnife, Gamma Knife and TomoTherapy)- Market Outlook 2022 US$ 750.00

... . The report “Global Radiotherapy Market by Products (Proton Therapy, Linear Accelerator, CyberKnife, Gamma Knife and TomoTherapy)- Market Outlook 2022” provides an in-depth analysis of global radiotherapy market focusing on external beam radiation therapy products such as Proton Therapy, Linear Accelerator, CyberKnife, Gamma Knife and TomoTherapy. Market analysis of aforementioned radiotherapy products has ...

Dec, 2016 57 pages
Global Proton Therapy Market Outlook 2021 US$ 800.00

The report “Global Proton Therapy Market Outlook 2021” provides an in-depth analysis of global proton therapy treatment market with focus on major regional market such as North America, Europe and Asia Pacific. North America is the world’s largest proton therapy market with ...

Dec, 2016 62 pages
Global Digital Therapeutics Market Research Report 2016 US$ 2,850.00

2016 Global Digital Therapeutics Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Digital Therapeutics industry, focusing on the main ... with: 1.) basic information; 2.) the Asia Digital Therapeutics industry; 3.) the North American Digital Therapeutics industry; 4.) the European Digital Therapeutics industry; 5.) market entry and investment feasibility; and ...

Nov, 2016 155 pages
Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022 US$ 1,800.00

... clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical ...

Dec, 2016 190 pages
Short Bowel Syndrome - Pipeline Review, H2 2016 US$ 2,000.00

Short Bowel Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome – Pipeline Review, H2 2016, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape. Short bowel syndrome ...

Dec, 2016 61 pages
Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016 US$ 3,500.00

... Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV ...

Nov, 2016 132 pages
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2016 US$ 2,000.00

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor – Pipeline Review, H2 2016, provides an overview of the Peripheral Nerve Sheath Tumor (Oncology) pipeline ...

Dec, 2016 112 pages
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Metachromatic Leukodystrophy (MLD) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System), complete with analysis by stage of development ...

Dec, 2016 41 pages
Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Infantile Spasm (West Syndrome) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System), complete with analysis by stage of development ...

Dec, 2016 63 pages
Huntington Disease - Pipeline Review, H2 2016 US$ 2,000.00

Huntington Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease – Pipeline Review, H2 2016, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape. Huntington's disease ...

Dec, 2016 292 pages
Familial Amyloid Neuropathies - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Familial Amyloid Neuropathies – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders), complete with analysis by stage of development ...

Dec, 2016 72 pages
Encephalopathy - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Encephalopathy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development ...

Dec, 2016 54 pages
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase... US$ 3,500.00

... Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) The report reviews Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A ...

Nov, 2016 40 pages
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2016 US$ 3,500.00

... Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) The report reviews Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics under ...

Nov, 2016 69 pages
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline... US$ 3,500.00

... for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine ...

Nov, 2016 102 pages
Ventricular Tachycardia - Pipeline Review, H2 2016 US$ 2,000.00

Ventricular Tachycardia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H2 2016, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape. Ventricular tachycardia ...

Nov, 2016 41 pages
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development ...

Nov, 2016 71 pages
Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development ...

Nov, 2016 65 pages
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H2 2016 US$ 3,500.00

... therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development ...

Nov, 2016 32 pages
Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development ...

Nov, 2016 39 pages
Post Operative Nausea And Vomiting - Pipeline Review, H2 2016 US$ 2,000.00

... Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Post Operative Nausea And Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development ...

Dec, 2016 50 pages
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 US$ 3,500.00

... Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase ...

Nov, 2016 67 pages
Nephrotic Syndrome - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development ...

Nov, 2016 45 pages
Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development ...

Nov, 2016 60 pages
Hypereosinophilic Syndrome - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development ...

Nov, 2016 52 pages
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development ...

Nov, 2016 36 pages
Hemochromatosis - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Hemochromatosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development ...

Nov, 2016 42 pages
Fanconi Anemia - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Fanconi Anemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of development ...

Nov, 2016 46 pages
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or... US$ 3,500.00

... Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) The report reviews E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like ...

Nov, 2016 66 pages
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 US$ 2,000.00

... Dravet Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

Nov, 2016 75 pages
Dermatomyositis - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Dermatomyositis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development ...

Nov, 2016 65 pages
Dermatomycoses - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomycoses (Infectious Disease), complete with analysis by stage of development ...

Nov, 2016 61 pages
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016 US$ 3,500.00

... Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Cell Division Cycle 7 Related ...

Nov, 2016 32 pages
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016 US$ 3,500.00

... Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development ...

Nov, 2016 52 pages
Canavan Disease - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development ...

Dec, 2016 29 pages
Brain Edema - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Brain Edema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Edema (Central Nervous System), complete with analysis by stage of development ...

Nov, 2016 40 pages
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016 US$ 3,500.00

... Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) The report reviews Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra ...

Nov, 2016 42 pages
Axial Spondyloarthritis - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development ...

Nov, 2016 103 pages
Global Plasma Therapy Market Research and Analysis, 2015-2021 US$ 3,495.00

... influencing the market guided by key recommendations. Analysis of regional regulations and other government policies impacting the global plasma therapy market Insights about market determinants which are stimulating the global plasma therapy market Detailed and extensive market segments with regional distribution ...

Sep, 2016 140 pages
Global Leukemia Therapeutic Market Research and Analysis, 2014-2020 US$ 3,495.00

Market Insight: Global Leukemia Market is expected to exceed $8.6 billion in 2020 with a CAGR 8.8% during 2015-2020. Leukemia is a lingering disease ... Leukemia Therapeutic market includes Clavis Pharma ASA, Pfizer, Ambit, Novartis, Bristol, Genzyme, Celgene Cephalon, Innate Pharma and so on. Leukemia market ...

Jul, 2016 140 pages
Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016 US$ 2,000.00

... pipeline guide Secondary (Hypogonadotropic) Hypogonadism – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development ...

Nov, 2016 63 pages
1 2 3 4 5 >
Skip to top